INCY - Incyte Corporation
73.45 -0.07 (-0.10%)
After hours: 6:15PM EDT
| Previous Close | 75.41 |
| Open | 75.03 |
| Bid | 73.51 x 800 |
| Ask | 73.45 x 900 |
| Day's Range | 73.45 - 75.15 |
| 52 Week Range | 57.00 - 88.83 |
| Volume | 870,411 |
| Avg. Volume | 1,297,624 |
| Market Cap | 15.753B |
| Beta (3Y Monthly) | 1.32 |
| PE Ratio (TTM) | 144.16 |
| EPS (TTM) | 0.51 |
| Earnings Date | Apr 30, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 89.25 |
- Zacks•2 hours ago
What's in Store for Vertex (VRTX) This Earnings Season?
On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.
- Zacks•6 hours ago
What's in the Cards for Amarin (AMRN) This Earnings Season?
Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.
- Zacks•7 hours ago
Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock?
During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.
- Zacks•9 hours ago
Solid Earnings Boost S&P, NASDAQ to New Closing Highs
Solid Earnings Boost S&P;, NASDAQ to New Closing Highs
- Zacks•9 hours ago
5 Biotech Stocks Defying the Medicare-for-All Scare
Unlike the broader healthcare sector, biotech stocks have notched up strong gains year to date.
- Zacks•9 hours ago
Can S&P 500 and Nasdaq Sustain Record Run? 5 Top Picks
The broad-market S&P 500 Index and tech-laden Nasdaq Composite closed at an all-time high level yesterday.
- Zacks•yesterday
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on sales growth.
- Zacks•yesterday
What's in the Cards for AstraZeneca (AZN) in Q1 Earnings?
AstraZeneca (AZN) will report first-quarter results on Apr 26. New drugs likely to drive sales.
- Zacks•yesterday
Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•yesterday
The Zacks Analyst Blog Highlights: CommScope, Ceridian HCM, Cabot Oil & Gas, Incyte and Snap
The Zacks Analyst Blog Highlights: CommScope, Ceridian HCM, Cabot Oil & Gas, Incyte and Snap
- Zacks•2 days ago
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?
During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
- Zacks•2 days ago
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.
- Zacks•2 days ago
Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?
While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.
- Zacks•2 days ago
5 Must-Buy Stocks Amid Exaggerated Economic Slowdown
The recently released three major economic data of March clearly indicated that the inherent strength of the economy remains intact.
- Simply Wall St.•5 days ago
Should Incyte (NASDAQ:INCY) Be Disappointed With Their 56% Profit?
Incyte Corporation (NASDAQ:INCY) shareholders have seen the share price descend 14% over the month. But the silver lining is the stock is up over five years. In that time, it is up 56%, which isn't bad, but is belo...
- Zacks•12 days ago
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group
Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
- Zacks•13 days ago
Concert Pharma Initiates Early-Stage Schizophrenia Study
Concert Pharmaceuticals (CNCE) announces initiation of multiple-ascending dose phase I study to evaluate its pipeline candidate, CTP-692, as an adjunctive treatment for schizophrenia.
- Business Wire•13 days ago
Incyte to Report First Quarter Financial Results
Incyte Corporation announced today that it has scheduled its first quarter 2019 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2019.
- Markit•15 days ago
See what the IHS Markit Score report has to say about Incyte Corp.
Incyte Corp NASDAQ/NGS:INCYView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for INCY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting INCY. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding INCY is favorable, with net inflows of $28.02 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- MarketWatch•16 days ago
Concert Pharmaceuticals' stock takes a sharp dive after disappointing patent appeal board ruling
Shares of Concert Pharmaceuticals Inc. took a sharp afternoon dive Monday, after the biopharmaceutical company said the patent trial and appeal board found that the claims of the patent on its alopecia areata treatment CTP-543 were "not patentable." The stock, which was little changed in afternoon trade just prior to the announcement, plunged 17% toward a 2-year low after the announcement. The company said the decision was appealable to the U.S. court of appeals. "While we're disappointed in this outcome, we believe we have strong arguments supporting the validity of our patent and intend to appeal the decision as we work to create additional intellectual property protecting CTP-543," said Chief Executive Roger Tung. In April 2017, Incyte Corp. had filed a petition challenging the validity of the patent on CTP-543. Incyte's stock slipped 0.1%. Over the past 12 months, Concert's stock has tumbled 43%, Incyte shares have rallied 29%, the iShares Nasdaq Biotechnology ETF has climbed 13% and the S&P 500 has gained 11%.
- Investor's Business Daily•20 days ago
Looking For Growth? Take A Look At These Biotechnology Stocks
The best biotech companies to invest in tend to have a commonality: A strong streak of earnings growth.
- Schaeffer's Investment Research•21 days ago
Puts Active After RBC Downgrades Incyte Stock
Most analysts are still bullish on the biotech name, though
- GlobeNewswire•22 days ago
BriaCell Announces Clinical Trial Collaboration Agreement with Incyte
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced a clinical trial collaboration and supply agreement (the “Agreement”) with Incyte (INCY), a global biopharmaceutical company focused on discovering and developing novel therapeutics in oncology and other serious diseases. The Agreement is focused on, but not limited to, the selection of novel combinations for the treatment of advanced breast cancer along with a planned clinical study of BriaCell’s lead candidate, Bria-IMT™, with Incyte’s selected compounds for advanced breast cancer.
- Insider Monkey•23 days ago
Did Hedge Funds Drop The Ball On Incyte Corporation (INCY) ?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth […]
